Background: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are attributed with the capacity to prevent cardiovascular diseases (CVD), chronic inflammation, and neurodegenerative diseases. Their bioactive contribution consists on interfering with lipid metabolism, decreasing inflammation, and increasing neuroprotection. Still, the findings imply that there is a considerable need for greater clarification of their mechanisms and their application to clinical care. Objectives: This narrative review is intended to discuss the potential target(s) of action, uses, and efficacy of ω-3 PUFAs in the context of CVD, inflammation, and neurodegenerative diseases. Materials and Methods: This narrative review was conducted through a comprehensive literature search using databases such as PubMed, Scopus, and Google Scholar. Studies published from the last 10 years were included, focusing on omega-3 fatty acids’ effects on cardiovascular, inflammatory, and neurological health. Both experimental and clinical studies were considered. Key search terms included “omega-3 fatty acids,” “eicosapentaenoic acid (EPA),” “docosahexaenoic acid (DHA),” “cardiovascular health,” “inflammation,” “neurological diseases,” and “safety profile.” The inclusion criteria were peerreviewed articles in English that provided relevant mechanistic insights and clinical outcomes. Results: EPA and DHA have been shown to reduce triglyceride levels, improve endothelial function, stabilize atherosclerotic plaques, and exhibit anti-arrhythmic properties. Inflammation is modulated through inhibition of nuclear factor kappa B and the production of specialized pro-resolving mediators such as resolvins and protectins. DHA also provides neuroprotection by enhancing membrane fluidity, reducing oxidative stress, and inhibiting apoptosis through the production of neuroprotection D1. Clinical trials such as the GISSI-prevenzione and Japan EPA lipid intervention study studies confirm the cardioprotective benefits of ω-3 supplementation. Conclusion: The evidence strongly supports the therapeutic potential of ω-3 PUFAs in CVDs, chronic inflammations, and neurodegenerative diseases. Given the various ways that these nutrients are now known to exert their effects from lipid modulation to neuroprotection, the latter would be useful in the prevention and management of diseases and promotion of health.

This chapter focuses on the activation and modulating function of the gut-brain axis in relation to memory and other cognitive functions. The gut-brain axis is a two-way communication system between the gastrointestinal system and the brain, closely regulated by the gut microbiota. Recent studies show that gut microbiota can modulate memory through neuroinflammation, neurotransmitter interactions, and effects on synaptic plasticity. Disruption of the gut microbiota, known as gut dysbiosis, has been linked to cognitive disorders and neurodegenerative diseases. This chapter will look at the effects of the gut microbiota on memory and explain how the pathways and signaling through the microbiota affect this relationship. It will also examine therapies that are thought to regulate the composition of the human gut microbiota to improve one’s memory and prevent aging. Additionally, the chapter discusses how gut-targeted therapies may be promising approaches toward enhancing cognitive health and optimal memory performance.

Worker motivation is a crucial factor for an organization's success, as it affects productivity and helps achieve its vision and objectives. Supervisors at specialized medical care institutions in Karachi face a challenge in achieving ideal motivation for their staff, which would significantly improve hierarchical execution. This study aims to understand the components that impact representative motivation and how it influences worker performance in these institutions. The research used an expressive exploration approach, with workers from Karachi's specialized medical care institutions as the focus. A Non-likelihood judgment analysis was used, and data was collected through Google structures and analyzed using SPSS software. Inferential measurements were used to assess the information. Results showed that worker motivation and the viability of data trade, as well as the nature of the workplace, had the most strong connection for external components, while representative motivation and occupation impact by partners had the least. The relationship between decency of treatment at work and worker motivation was the most strong, while the relationship between input on presentation and strengthening and representative independence and worker motivation was the most precarious. In conclusion, the study reveals significant strengths in the relationship between dependent and autonomous components, the significant impact of external and internal variables on worker motivation, and a basic impact of worker motivation on worker performance.

Introduction/Objective: Polycystic ovarian syndrome (PCOS) is a common endocrine and metabolic disorder whose reproductive, metabolic, and inflammatory features are not adequately addressed by existing single-mechanism therapies. A1, a novel 7-azaindole derivative (1-methyl -4- {1H-pyrrol [2,3-b] pyridine-3-yl-1, 2, 3, 6-tetrahydropyridine), was selected based on its structural resemblance to melatonin, which has been reported to possess antidiabetic properties. This study evaluated the reproductive, hormonal, and glycemic effects of A1 for the treatment of PCOS in a rat model. Methods: Sixty virgin female Albino Wistar rats (n=15/group across four groups: control, negative control/PCOS, standard [metformin], and A1-treated) were induced with PCOS by administering oral letrozole and were treated with A1 for 30 days. A subset of animals (n=3/group) received extended treatment for 60 days to assess subchronic toxicity. Evaluations included ovarian histopathology, hormonal assays, glycemic parameters, lipid profiling, cytotoxicity assays, molecular docking, and gene expression analysis. Results: A1 treatment eliminated ovarian cysts, restored estrous cyclicity (89.36% by day 21-28, versus 0% in the PCOS group), improved lipid profiles, and restored hormonal profiles (reducing testosterone, LH, and estradiol while increasing FSH and SHBG toward control values; p<0.01). A1 exhibited alpha-glucosidase inhibitory activity (63.45% inhibition; IC50 88±5.7 μM) and antioxidant activity (83.25% DPPH scavenging at 100 μg/ml). However, extended administration was associated with histological changes in the liver and kidney suggestive of potential hepatic and renal stress, which warrants confirmation with biochemical toxicity markers. Discussion: A1's therapeutic effects likely reflect combined hormonal restoration and glucose-lowering activity consistent with its structural resemblance to melatonin, while the predicted FSHR interaction identified by molecular docking remains a computational hypothesis that has not yet been functionally validated. The hepatic and renal histological changes observed after extended dosing, together with the absence of biochemical toxicity markers and in vivo pharmacokinetic data, indicate that further structural optimization and toxicological characterization are needed before A1 can be considered for clinical development. Conclusion: A1 significantly restored endocrine and hormonal markers, glucose, insulin, and dyslipidemia while enhancing FSHR gene expression; molecular docking predicted binding within the FSHR allosteric pocket, a finding not yet functionally validated. These results indicate that A1, a novel 7-azaindole derivative, may regulate reproductive and metabolic dysfunctions in PCOS through endocrine modulation and receptor-- mediated mechanisms, demonstrating significant therapeutic potential for PCOS and ameliorating key metabolic and endocrine disturbances. While promising, its toxicity profile warrants further structural optimization for clinical development.